News
Vamousse™ head lice preventative shampoo coming to market in the USA
20 January 2014
TyraTech, Inc. (AIM: TYR and TYRU) a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce its pioneering, over-the-counter head lice preventative shampoo product, Vamousse™, is now listed with the USA Food and Drug Administration ("FDA") and will be available for sale in the USA from the end of Q1 2014. The Vamousse Preventative Shampoo is a new product in the Vamousse range of head lice products and complements the Vamousse Treatment.
The Vamousse™ preventative shampoo product is targeting a new market, the prevention rather than the treatment of head lice infestation. The product provides a unique solution to help prevent head lice infestation. The shampoo can be used on a regular basis to prevent head lice infestation in children in at-risk situations (sleep-overs, camps, sports, events with friends, etc.) as well as to protect the whole family when an infestation occurs in one of its members. TyraTech believes that this product has the potential to give it access to a new market segment for prevention and for routine use of the product whereas existing head lice treatments are only used on an emergency basis and only for individuals that are already infested.
In addition, the new Vamousse™ preventative shampoo product will enable TyraTech to further expand its market penetration by offering a larger range of products for both head lice treatment and prevention. TytraTech believes that the Vamousse Preventative Shampoo will be distributed initially on-line and in brick-and-mortar distributors in the USA.
Bruno Jactel, Chief Executive Officer, said: "We have been working diligently to accelerate the development of this breakthrough preventative head lice shampoo targeting a new and potentially significant market. We are delighted to announce that we are now FDA listed and ready to launch in the US market. This product will be available soon in traditional retail and internet-based distributors. We feel confident that TyraTech's unique and complete product offering will help us to establish a significant market presence. TyraTech believes it is well positioned to meet market expectations for 2014 revenues."
Further information on Vamousse™ is available on the Company's website at:
http://www.tyratech.com/content/company-products/head-lice.asp
For further information please contact:
| TyraTech Inc. Alan Reade, Non-Executive Chairman Bruno Jactel, Chief Executive Officer |
Tel: +44 7841978709 Tel: +1 919 415 4340 |
| SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady |
Tel: +44203 368 3551 |
| Allenby Capital Limited , Joint Broker Chris Crawford |
Tel: +44 20 3328 5656 |
| Whitman Howard Limited, Joint Broker Ranald Mc-Gregor Smith / Niall Devins |
Tel: +44 20 7087 4555 |
| Walbrook, Financial PR and IR Bob Huxford /Guy McDougall (Public Relations) Paul Cornelius (Investor Relations) |
Tel: +44 20 7933 8792 Tel: +44 20 7933 8794 |
Disclaimer for U.S. Site Visitors
This web site contains investor-related information which is restricted to non-U.S. persons or Qualified Institutional Buyers as defined in Rule 144A of the U.S. Securities Act of 1933, as amended (the "Securities Act"). The information provided herein is not an offer to buy or sell, or a solicitation of an offer to buy or sell, any TyraTech, Inc. securities. By viewing pages on this web site, you agree and acknowledge that TyraTech, Inc.'s common stock has not been registered under the Securities Act and that you are a non-U.S. person, Qualified Institutional Buyer as defined in Rule 144A of the Securities Act., or you are not holding, acquiring or selling TyraTech, Inc. common stock for the account or benefit of any U.S. person.